Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Drug-disease modeling in the pharmaceutical industry - where mechanistic systems pharmacology and statistical pharmacometrics meet.
Helmlinger G, Al-Huniti N, Aksenov S, Peskov K, Hallow KM, Chu L, Boulton D, Eriksson U, Hamrén B, Lambert C, Masson E, Tomkinson H, Stanski D. Helmlinger G, et al. Among authors: chu l. Eur J Pharm Sci. 2017 Nov 15;109S:S39-S46. doi: 10.1016/j.ejps.2017.05.028. Epub 2017 May 12. Eur J Pharm Sci. 2017. PMID: 28506868 Review.
Quantitative Systems Pharmacology: An Exemplar Model-Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development.
Helmlinger G, Sokolov V, Peskov K, Hallow KM, Kosinsky Y, Voronova V, Chu L, Yakovleva T, Azarov I, Kaschek D, Dolgun A, Schmidt H, Boulton DW, Penland RC. Helmlinger G, et al. Among authors: chu l. CPT Pharmacometrics Syst Pharmacol. 2019 Jun;8(6):380-395. doi: 10.1002/psp4.12426. Epub 2019 Jun 11. CPT Pharmacometrics Syst Pharmacol. 2019. PMID: 31087533 Free PMC article. Review.
Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors.
Yakovleva T, Sokolov V, Chu L, Tang W, Greasley PJ, Peilot Sjögren H, Johansson S, Peskov K, Helmlinger G, Boulton DW, Penland RC. Yakovleva T, et al. Among authors: chu l. Diabetes Obes Metab. 2019 Dec;21(12):2684-2693. doi: 10.1111/dom.13858. Epub 2019 Sep 9. Diabetes Obes Metab. 2019. PMID: 31423699
Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling.
Sokolov V, Yakovleva T, Chu L, Tang W, Greasley PJ, Johansson S, Peskov K, Helmlinger G, Boulton DW, Penland RC. Sokolov V, et al. Among authors: chu l. CPT Pharmacometrics Syst Pharmacol. 2020 Apr;9(4):222-229. doi: 10.1002/psp4.12498. Epub 2020 Mar 6. CPT Pharmacometrics Syst Pharmacol. 2020. PMID: 32064793 Free PMC article.
Evaluation of Combination Strategies for the A2AR Inhibitor AZD4635 Across Tumor Microenvironment Conditions via a Systems Pharmacology Model.
Voronova V, Peskov K, Kosinsky Y, Helmlinger G, Chu L, Borodovsky A, Woessner R, Sachsenmeier K, Shao W, Kumar R, Pouliot G, Merchant M, Kimko H, Mugundu G. Voronova V, et al. Among authors: chu l. Front Immunol. 2021 Mar 2;12:617316. doi: 10.3389/fimmu.2021.617316. eCollection 2021. Front Immunol. 2021. PMID: 33737925 Free PMC article.
3,101 results